Enobia Pharma is a Canadian biotechnology company founded in 1997, dedicated to developing therapies for serious genetic bone disorders with no approved treatments. Their lead product, ENB-0040, is a subcutaneous bone-targeted enzyme replacement therapy designed for the rare disease hyposphostasia. The company specializes in the industries of Biotechnology and Health Care. Enobia Pharma received a significant $40.00M in Venture Round investment on 08 August 2011. This substantial investment reflects both the potential for their innovative therapeutic approaches and the confidence of investors in their ability to address unmet medical needs within the field of genetic bone disorders.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $40.00M | - | 08 Aug 2011 | |
| Venture Round | $15.00M | - | 01 Apr 2011 | |
| Series C | $50.00M | 4 |
|
10 Aug 2009 |
| Series B | $40.10M | 5 |
|
01 Aug 2007 |
| Series A | $15.55M | 1 | T2C2 Capital | 18 Jan 2005 |
No recent news or press coverage available for Enobia Pharma.
We care about your data, and we'd love to use cookies make your experience better.
